Related references
Note: Only part of the references are listed.Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses
Hsiang Ying Lee et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2021)
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses
Jiun-Ruey Hu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal D. Shore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism
Pamela L. Lutsey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A diagnostic accuracy study validating cardiovascular ICD-9-CM codes in healthcare administrative databases. The Umbria Data Value Project
Francesco Cozzolino et al.
PLOS ONE (2019)
A population-based study of cardiovascular diseasemortality risk in US cancer patients
Kathleen M. Sturgeon et al.
EUROPEAN HEART JOURNAL (2019)
Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients
Pamela L. Lutsey et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
Daniel J. Khalaf et al.
LANCET ONCOLOGY (2019)
Clinical outcomes among patients treated with abiraterone acetate for advanced prostate cancer with pre-existing cardiovascular conditions
Grace Lu-Yao et al.
CANCER RESEARCH (2019)
Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
Pamela L. Lutsey et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2019)
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer
Roberto Iacovelli et al.
CLINICAL GENITOURINARY CANCER (2018)
Cardiovascular toxicities of systemic treatments of prostate cancer
Antonello Veccia et al.
NATURE REVIEWS UROLOGY (2017)
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
Neal D. Shore et al.
LANCET ONCOLOGY (2016)
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
Karim Fizazi et al.
LANCET ONCOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Charlson Comorbidity Index in Ischemic Stroke and Intracerebral Hemorrhage as Predictor of Mortality and Functional Outcome after 6 Months
Pedro Enrique Jimenez Caballero et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The incident user design in comparative effectiveness research
Eric S. Johnson et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2013)
Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins
Goodarz Danaei et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A systematic review of validated methods for identifying heart failure using administrative data
Jane S. Saczynski et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review
Isla M. Ogilvie et al.
AMERICAN JOURNAL OF MEDICINE (2010)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
William P. Harris et al.
NATURE CLINICAL PRACTICE UROLOGY (2009)
Observational Studies Analyzed Like Randomized Experiments An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease
Miguel A. Hernan et al.
EPIDEMIOLOGY (2008)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mineralocorticoid receptor activation causes cerebral vessel remodeling and exacerbates the damage caused by cerebral ischemia
AM Dorrance et al.
HYPERTENSION (2006)
Evaluating medication effects outside of clinical trials: New-user designs
WA Ray
AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)
Share Paper
